Canada markets closed

Rakovina Therapeutics Inc. (RKV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.0800-0.0050 (-5.88%)
At close: 09:47AM EDT

Rakovina Therapeutics Inc.

1008 Beach Avenue
Suite 105
Vancouver, BC V6E 1T7

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey A. Bacha B.Sc., M.B.A.Executive Chairman120kN/A1968
Mr. David Hyman CA, CBVCFO & Corporate Secretary120kN/A1973
Dr. Mads DaugaardPresident, CEO & Chief Scientific OfficerN/AN/AN/A
Dr. John Langlands Ph.D.Chief Operating OfficerN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Rakovina Therapeutics Inc. engages in the research and development of new cancer treatments based on novel series of small-molecule DNA-damage response inhibitors (DDRi). Its preclinical product pipeline include kt-2000, a next generation oral targeted small molecule PARP inhibitors; kt-3000, a bi-functional small-molecule drug candidate; and kt-4000, a DNA-damaging DDR inhibitors. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada.Rakovina Therapeutics Inc operates as a subsidiary of NewGen Therapeutics, Inc.

Corporate Governance

Rakovina Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.